200 related articles for article (PubMed ID: 31626571)
1. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
3. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
4. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
5. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
6. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Plütschow A; Mottok A; Bernd HW; Feller AC; Ott G; Cogliatti S; Fend F; Quintanilla-Martinez L; Stein H; Klapper W; Möller P; Rosenwald A; Engert A; Hansmann ML; Eichenauer DA
Am J Hematol; 2019 Nov; 94(11):1208-1213. PubMed ID: 31396979
[TBL] [Abstract][Full Text] [Related]
7. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
9. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Hartmann S; Eichenauer DA; Plütschow A; Mottok A; Bob R; Koch K; Bernd HW; Cogliatti S; Hummel M; Feller AC; Ott G; Möller P; Rosenwald A; Stein H; Hansmann ML; Engert A; Klapper W
Blood; 2013 Dec; 122(26):4246-52; quiz 4292. PubMed ID: 24100447
[TBL] [Abstract][Full Text] [Related]
11. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
Müller RP; Eich HT
Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
13. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
Olszewski AJ; Shrestha R; Cook NM
Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
[TBL] [Abstract][Full Text] [Related]
14. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Müller H; Elger L; Goergen H; Fuchs M; Kreissl S; Böll B; Diehl V; von Tresckow B; Borchmann P; Engert A
Br J Haematol; 2021 May; 193(3):515-519. PubMed ID: 33486762
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
18. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
[TBL] [Abstract][Full Text] [Related]
20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
